Leaflet: information for the user
Enalapril/lercanidipino cinfa 20 mg/10 mg film-coated tablets
Enalapril maleate/lercanidipine hydrochloride
Read this leaflet carefully before you start to take this medicine, because it contains important information for you.
enalapril/lercanidipino cinfa is a fixed combination of an ACE inhibitor (enalapril) and a calcium channel blocker (lercanidipino), two medications that reduce blood pressure.
enalapril/lercanidipino cinfa is used to treat high blood pressure (hypertension) in adult patients whose blood pressure is not adequately controlled by enalapril 20 mg alone. enalapril/lercanidipino cinfa should not be used for the initial treatment of hypertension.
Do not takeenalapril/lercanidipino cinfa
Warnings and precautions
Consult your doctor or pharmacist before starting to take enalapril/lercanidipino cinfa.
Your doctor may review your kidney function, blood pressure, and the amount of electrolytes (e.g., potassium) in your blood at regular intervals.
Also, see the information included under the heading “Do not take enalapril/lercanidipino cinfa”.
If you are about to undergo surgery or certain treatments soon.
If you are about to undergo any of the following procedures, inform your doctor that you are taking enalapril/lercanidipino:
You should inform your doctor if you think you are (or may be) pregnant or if you are breastfeeding (see the section Pregnancy, breastfeeding, and fertility).
Children and adolescents
The safety and efficacy of enalapril/lercanidipino have not been established in children under 18 years of age.
Other medicines and enalapril/lercanidipino cinfa
Enalapril/lercanidipino should not be taken with certain medicines.
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine.
This is because when enalapril/lercanidipino is taken with certain medicines, the effect of enalapril/lercanidipino or the other medicines may be modified, or certain adverse effects may occur more frequently.
Specifically, inform your doctor or pharmacist if you are taking any of the following medicines:
Do not take enalapril/lercanidipino if you have taken or are currently taking sacubitrilo/valsartan, a medicine used to treat chronic heart failure in adults, as the risk of angioedema (rapid swelling of the throat) increases.
If you are taking any of the following medicines, the risk of angioedema may be increased:
Your doctor may need to adjust your dose and/or take other precautions:
Taking enalapril/lercanidipino cinfa with food, drinks, and alcohol
Enalapril/lercanidipino should be taken at least 15 minutes before meals.
A fatty meal significantly increases the levels of the medicine in the blood.
Alcohol may increase the effect of enalapril/lercanidipino. During treatment with enalapril/lercanidipino, alcohol should not be consumed. Enalapril/lercanidipino should not be taken with grapefruit or grapefruit juice, as it may increase its antihypertensive effect (see “Do not take enalapril/lercanidipino cinfa”).
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medicine.
Pregnancy and fertility
You should inform your doctor if you think you are (or may be) pregnant. Generally, your doctor will advise you to stop taking enalapril/lercanidipino before becoming pregnant or as soon as you know you are pregnant and recommend taking another medicine instead of enalapril/lercanidipino. Enalapril/lercanidipino is not recommended for use in women who may become pregnant or at the beginning of pregnancy, and it should not be taken if you are more than three months pregnant, as it may severely harm the fetus if used after the third month of pregnancy.
Breastfeeding
Enalapril/lercanidipino should not be taken during breastfeeding.
Driving and operating machinery
If you experience dizziness, weakness, or somnolence with this medicine, you should not drive or operate machinery.
Enalapril/lercanidipino cinfa contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially “sodium-free”.
Adults: unless your doctor tells you otherwise, the recommended dose is one tablet once a day, at the same time every day. The tablet should be taken preferably in the morning, at least 15 minutes before breakfast. The tablets should be swallowed whole with water. See “Taking enalapril/lercanidipino cinfa with food, drinks, and alcohol”.
Patients with kidney problems/elderly patients: your doctor will decide the medication dose you should take, taking into account how well your kidneys are functioning.
If you take more enalapril/lercanidipino cinfa than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately, or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested. Bring the packaging and the medication leaflet to the healthcare professional.
A dose higher than the correct one may cause excessive blood pressure drop and your heart may beat irregularly or faster.
If you forgot to take enalapril/lercanidipino cinfa
If you interrupt the treatment with enalapril/lercanidipino cinfa
Do not stop taking your medication, unless your doctor tells you to.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them..This medicine may cause the following side effects:
Some side effects may be serious.
Inform your doctor immediately if you notice any of the following side effects:
When you start taking enalapril/lercanidipino, you may feel weakness or dizziness, or notice that your vision becomes blurry; this is caused by a sudden drop in blood pressure, and if it happens, it will be helpful to lie down. If you are concerned, consult your doctor.
Side effects observed with enalapril/lercanidipino
Frequent(may affect up to 1 in 10 patients)
Cough, feeling of dizziness, headache.
Infrequent(may affect up to 1 in 100 patients)
Changes in blood parameters, such as a decrease in platelet count, an increase in potassium levels in the blood, nervousness (anxiety), feeling of dizziness when standing up, vertigo, rapid or irregular heartbeat (palpitations), sudden redness of the face, neck, or upper chest (erythema), low blood pressure, abdominal pain, constipation, feeling sick (nausea), increased levels of liver enzymes, skin redness, joint pain, increased urination frequency, feeling weak, fatigue, feeling hot, inflammation of the ankles.
Rare(may affect up to 1 in 1,000 patients)
Anemia, allergic reactions, ringing in the ears (tinnitus), fainting, dry throat, sore throat, indigestion, salty taste in the tongue, diarrhea, dry mouth, gum inflammation, allergic reaction with swelling of the face, lips, tongue, or throat that causes difficulty breathing or swallowing, skin rash, urticaria, nocturia, large amounts of urine production, impotence.
Additional side effects observed with enalapril or lercanidipino alone
Enalapril
Very frequent(may affect more than 1 in 10 patients)
Blurry vision, feeling of dizziness, weakness, or discomfort, and cough.
Frequent(may affect up to 1 in 10 patients)
Depression, headache, fainting (syncope), chest pain, dizziness due to low blood pressure, changes in heart rate, rapid or irregular heartbeat (palpitations), angina, shortness of breath, alterations in taste, increased levels of creatinine in the blood (usually detected through a blood test), high potassium levels in the blood, diarrhea, abdominal pain, fatigue (fatigue), rash, allergic reaction with swelling of the face, lips, tongue, or throat that causes difficulty breathing or swallowing.
Infrequent(may affect up to 1 in 100 patients)
Anemia (including aplastic and hemolytic anemia), sudden drop in blood pressure, confusion, nervousness, somnolence or insomnia, feeling of pins and needles or numbness, myocardial infarction (possibly caused by very low blood pressure in certain high-risk patients, including those with heart or brain blood supply problems), stroke (possibly due to very low blood pressure in high-risk patients), nasal congestion, sore throat, and hoarseness, asthma associated with chest tightness, slowed movement of food through the intestines (ileus), pancreatitis, feeling sick (vomiting), indigestion, constipation, stomach irritation (gastritis), dry mouth, ulcers, anorexia, itching or urticaria, hair loss, renal function alteration, renal insufficiency, increased sweating, high levels of protein in the urine (measured through a blood test), muscle cramps, general feeling of discomfort, high temperature (fever), low blood sugar or sodium levels, high levels of urea in the blood (all measured through a blood test), redness, rapid or irregular heartbeat (palpitations), vertigo (dizziness), tinnitus (ringing in the ears), impotence.
Rare(may affect up to 1 in 1,000 patients)
Changes in blood parameters, such as a decrease in white blood cell count, bone marrow depression, autoimmune diseases, strange dreams or sleep disorders, Raynaud's phenomenon (in which hands and feet may become intensely cold and acquire a white color due to low blood flow), nasal inflammation, pneumonia, liver problems, such as decreased liver function, liver inflammation, jaundice (yellowing of the skin or eyes), increased levels of liver enzymes or bilirubin (measured through a blood test), erythema multiforme (red spots of different shapes that appear on the skin), Stevens-Johnson syndrome, and toxic epidermal necrolysis (a severe skin condition characterized by skin redness and scaling, blistering, or open sores), dermatitis exfoliativa/erythrodermia (severe skin rash with peeling or skin shedding), pemphigus (small blisters filled with fluid on the skin), decreased urine production, gynecomastia (breast enlargement in men), inflamed glands in the neck, armpits, or groin, fluid or other substance accumulation in the lungs (visible on X-rays), inflammation of the cheeks, gums, tongue, lips, and throat.
Very rare(may affect up to 1 in 10,000 patients)
Intestinal angioedema.
Unknown frequency(cannot be estimated from available data)
Excessive production of antidiuretic hormone causing fluid retention, leading to weakness, fatigue, or confusion.
A set of symptoms has been reported that may include one or more of the following: fever, inflammation of blood vessels (serositis, vasculitis), muscle pain (myalgia, myositis), joint pain (arthralgia/arthritis). It may cause a rash, photosensitivity, or other skin manifestations.
Lercanidipino
Some of these side effects may be serious. If you experience any of these side effects,consult your doctor.
Rare(may affect up to 1 in 1,000 patients)
Angina pectoris (chest pain caused by heart blood supply lack), allergic reactions (with symptoms such as itching, rash, urticaria), fainting.
Patients with pre-existing angina pectoris may experience an increase in frequency, duration, or severity of attacks associated with treatment with the group of medications to which lercanidipino belongs. Isolated cases of myocardial infarction have been observed.
Other possible side effects:
Frequent(may affect up to 1 in 10 patients): headache, rapid or irregular heartbeat (palpitations), sudden redness of the face, neck, or upper chest, swelling of the ankles.
Infrequent(may affect up to 1 in 100 patients): dizziness, low blood pressure, stomach burning, discomfort, stomach pain, skin rash, itching, muscle pain, increased urine production, weakness or fatigue.
Rare(may affect up to 1 in 1,000 patients): somnolence, vomiting, diarrhea, urticaria, increased urination frequency, chest pain.
Unknown frequency(cannot be estimated from available data): gum swelling, changes in liver function (detected through blood tests), cloudy fluid (during hemodialysis through a tube inside the abdomen), swelling of the face, lips, tongue, or throat that may cause difficulty breathing or swallowing.
If any of the side effects worsen, or if you experience any type of side effect that does not appear in this prospectus, inform your doctor or pharmacist. You can consult your doctor or pharmacist for more information about side effects, as they have a more complete list of side effects.
Reporting side effects
If you experience any type of side effect,consult your doctor or pharmacist, evenifit is a possible side effect thatdoes not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 25°C.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of enalapril/lercanidipino cinfa
Tablet core: microcrystalline cellulose, sodium hydrogen carbonate, pregelatinized cornstarch, sodium carboxymethylcellulose (type A) (from potato), anhydrous colloidal silica, and magnesium stearate.
Coating: hypromellose, macrogol 6000, talc, titanium dioxide (E-171), and yellow iron oxide (E-172).
Appearance of the product and contents of the package
Yellowish clear to yellowish round and biconvex film-coated tablets.
They are presented in blisters of polyamide-aluminum-PVC/aluminum.
Each package contains 28 tablets.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Cinfa Laboratories, S.A.
Carretera Olaz-Chipi, 10. Industrial Estate Areta
31620 Huarte (Navarra) - Spain
Responsible for manufacturing
TEVA Gyógyszergyár Zrt.
Pallagi street 13, Debrecen H-4042
Hungary
or
Teva Pharma S.L.U.
C/ C, nº 4, Industrial Estate Malpica
Zaragoza 50016
or
Merckle GmbH
Ludwig-Merckle Street 3
Blaubeuren 89143
Germany
or
Cinfa Laboratories, S.A.
Carretera Olaz-Chipi, 10. Industrial Estate Areta
31620 Huarte (Navarra) - Spain
Last review date of this leaflet:February 2022
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)www.aemps.gob.es
You can access detailed and updated information on this medicine by scanning the QR code included in the leaflet and packaging with your smartphone. You can also access this information at the following internet address:https://cima.aemps.es/cima/dochtml/p/79821/P_79821.html
QR code to:https://cima.aemps.es/cima/dochtml/p/79821/P_79821.html
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.